If this is where you are
Newly diagnosedReports arriving, no plan yetAlready tested elsewhereYou have results you cannot readOn treatment nowYou want to know it is workingOr
Finished treatmentWatching for anything left behindWorried about familyInherited risk, and relativesWanting a second opinionA decision you are unsure aboutDecide
Blueprint CareThe flagship decision report and a dedicated clinical teamSignalOne free question answered on WhatsApp within four hoursNavigationRecords you already have, turned into a clarity timelineDecipherInterpretation of sequencing already done elsewhereTest
Signature, all tiersSolid tumour and blood cancer panels comparedSignature STb33 genes from a blood drawSignature STb O118 genes from a blood drawSignature STb O+523 genes, with TMB and MSISignature STt OProfiling from an existing tissue blockMonitor
SentinelSerial monitoring while treatment is runningSentinel SolidctDNA monitoring for solid tumoursClearMolecular residual disease surveillanceClear SolidTumour-informed surveillanceProtect
HeritageInherited risk, assessed properlyHeritage CoreA broad inherited-risk assessmentHeritage AdhocFocused testing for named relativesCancer DictionaryWhat is discussed in your specific cancerReference
Cancer DictionaryOne structured entry per cancer typeBiomarker LibraryOne page per marker, in plain languagePatient ResourcesGlossary, guides and how to use themWatch, read and ask
Video LibraryShort explainers, captioned and translatedStoriesPatient and clinician experiences, consentedFAQThe questions we are asked mostCancer Dictionary · Thoracic
Small cell lung cancer usually responds quickly to initial treatment and relapses quickly too. It carries a high mutation burden but few of the clean, single-gene targets that shaped non-small cell practice. Transcriptional subtypes and specific surface targets are the active areas of research rather than settled practice.
Also called SCLC, Small cell carcinoma of the lung.
Start here
Small cell lung cancer is defined by pace rather than by a targetable driver, so the discussion turns on timing and on emerging subtype biology rather than on a single actionable alteration.
Small cell lung cancer usually responds quickly to initial treatment and relapses quickly too. It carries a high mutation burden but few of the clean, single-gene targets that shaped non-small cell practice. Transcriptional subtypes and specific surface targets are the active areas of research rather than settled practice.
01Before any molecular question
Usually established first: the histological diagnosis, and whether disease is limited or extensive in extent. Because the disease moves quickly, the interval between diagnosis and starting treatment is often short, which shapes what testing is practical.
Usually already established
02
The divisions below are not labels. Each one changes what the treatment discussion is actually about.
Limited stage
Disease confined enough to be encompassed in a radiation field. Combined-modality treatment organises the discussion.
Extensive stage
Disease beyond that. Systemic treatment leads, with immunotherapy now part of the standard discussion.
Transformed small cell
Small cell histology arising in a patient previously treated for non-small cell lung cancer, usually on a targeted agent. Biologically important, because it explains a resistance pattern rather than being a new diagnosis.
03What is discussed
Near-universal loss of TP53 and RB1 function is characteristic, and their presence is more descriptive than actionable. Tumour mutational burden is typically high. Research attention centres on transcriptional subtypes defined by ASCL1, NEUROD1, POU2F3 and inflamed phenotypes, and on surface targets such as DLL3 that are relevant to newer treatment classes. MYC family amplification and SLFN11 expression are also discussed in research settings.
TP53 and RB1
Loss of both is characteristic and helps confirm the biology, rather than pointing to a treatment.
DLL3
A surface target relevant to newer therapeutic classes rather than a genomic finding.
Transcriptional subtype
ASCL1, NEUROD1, POU2F3 and inflamed subtypes are research classifications, not routine reporting.
TMB
Usually high, in a disease where immunotherapy is part of the standard discussion.
SLFN11
Studied in relation to DNA-damaging treatment sensitivity.
This is not an exhaustive list, and which markers are relevant depends on the individual case. Not every marker listed is assessed in every patient.
04What is tested, and from what
Comprehensive profiling changes first-line treatment less often here than in non-small cell disease, and the pace of the illness means a result that takes weeks may arrive after treatment has started. Where profiling is done, the common reasons are trial eligibility, confirming a transformation from a prior non-small cell cancer, or an atypical presentation that raises doubt about the diagnosis itself.
Small cell lung cancer tends to shed ctDNA readily, which makes plasma a practical window when tissue is limited. Serial ctDNA is under study as an early signal of relapse in a disease where relapse is common and often rapid.
More on ctDNA monitoring05The timing question
Testing that arrives after the decision it was meant to inform has already been made is a common and avoidable problem. This is the sequence in which molecular information tends to become relevant.
06Take these to your team
When a decision is being made
Questions worth raising with a treating team.
At progression, recurrence or resistance
The molecular picture at diagnosis is not always the molecular picture later.
07What shapes eligibility
Trial activity in small cell lung cancer is substantial and often organised around surface targets, DNA damage response, and subtype biology. Prior therapy and the treatment-free interval are frequently written into eligibility criteria.
| Term | What it means |
|---|---|
| Limited and extensive stage | A two-part staging shorthand specific to small cell lung cancer, based on whether disease fits in a radiation field. |
| Transformation | When a cancer changes cell type under treatment pressure. Small cell transformation is a known resistance route in EGFR-mutant lung cancer. |
| Transcriptional subtype | A grouping based on which genes the tumour is actively switching on, rather than which genes are mutated. |
These are the services most often relevant to this cancer. Which of them applies is a clinical question, not an automatic one.
This entry is educational. It describes what is commonly discussed in this cancer, not what should happen for any individual. Which of it applies depends on the specific diagnosis, stage, prior treatment and the person themselves. Nothing here is a recommendation, and no list of biomarkers here is exhaustive. Decisions belong with a treating team who know the whole case.
Take the next step
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationCommission your decision report and a dedicated clinical team.
Explore Blueprint CareSignal replies to your first question within four hours, at no cost.
Start with Signal